相关实验视频
Updated: Sep 9, 2025

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
347
GLP-1受体激动剂对自杀行为的影响:基于随机对照试验的元分析
Jingqi Chen1, Qiufeng Zhang1, Qingping Wu1
1The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.
Journal of diabetes
|September 1, 2025
概括
在2型糖尿病 (T2DM) 或肥胖症患者中,葡萄糖类-1受体激动剂 (GLP-1RA) 与自杀行为没有显著的关联. 这项对25项RCT的分析在各个子组和GLP-1类型的RA中没有发现风险增加.
科学领域:
- 内分泌学
- 精神病学
- 药物监督管理
背景情况:
- 葡萄糖类-1受体激活剂 (GLP-1RA) 广泛用于治疗2型糖尿病 (T2DM) 和肥胖.
- 人们对GLP-1 RA使用与自杀行为之间可能存在的关联表示担忧.
- 需要强有力的证据来澄清这种风险.
研究的目的:
- 进行元分析,评估GLP-1RA暴露与自杀行为发生率之间的关联.
- 在T2DM和/或肥胖患者群体中评估这种关联.
主要方法:
- 在主要电子数据库 (PubMed,科学网,科克莱恩图书馆,临床试验.gov) 进行了全面的文献搜索.
- 包括25个随机对照试验 (RCT) 的数据.
- 为了量化相关性,计算了风险比率 (RR) 和95%信心区间 (95% CI).
主要成果:
- 整体元分析显示GLP- 1 RA与对照组之间的自杀行为发生率没有显著差异 (RR=0.84,95% CI:0.54-1.32,p=0.46).
- 根据疾病 (T2DM,肥胖症),年龄 (青少年,成年人),特定GLP-1RA和比较剂 (安慰剂) 分层的亚组分析也显示没有显著的关联.
- 对于特定类型的自杀行为,包括想象,尝试,与抑郁症相关的自杀和完成的自杀,没有发现显著差异.
结论:
- 这些发现表明GLP-1 RA使用与2型糖尿病或肥胖患者自杀行为的风险增加没有显著关联.
- 这些结果提供了关于GLP-1RA与自杀行为的安全概况的保证.
相关概念视频
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395
Dipeptidyl Peptidase 4 Inhibitors
252
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
252
G-protein Coupled Receptors
121.2K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
121.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones
288
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
288
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340

